First in Human Study Evaluating Single Ascending Oral Doses of YCT-529 in Healthy Males

Double-blind, Placebo Controlled, First in Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of YCT-529

A single ascending oral dose(s) study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of YCT-529 in healthy male subjects.

Study Overview

• Status: Completed
• Conditions: Male Contraception
• Intervention / Treatment: Drug: YCT-529; Drug: YCT-529 Placebo

Detailed Description

This is a Phase 1a, double-blind, placebo controlled, first in human study to evaluate the safety, tolerability, PK, and PD of YCT-529 in 2 cohorts of 8 subjects. Cohorts 1 and 2 will be dosed in the fasted state in Periods 1 and 2. Each cohort will receive two doses of study drug separated by a washout period. One cohort will then return for a third dose of study drug under fed conditions in Period 3 to study the effect of food on YCT-529.

• Study Type: Interventional
• Enrollment (Actual): 16
• Phase: Phase 1

Contacts and Locations

Study Locations

• United Kingdom
  • East Midlands
    • Nottingham, East Midlands, United Kingdom, NG11 6JS
      • Quotient Sciences

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Male subject in good health as confirmed by physical examination, medical history, and clinical laboratory tests of blood and urine at the time of Screening.
2. Subject must provide written informed consent.
3. Subject must be willing and able to communicate and participate in the whole study.
4. Subject is 25 to 60 years of age (inclusive).
5. Subject has been vasectomized for at least 6 months prior to enrolment
6. Subject has body mass index (BMI) 18.0 to 32.0 kg/m2.
7. Subject has no history of hormonal therapy uses in the 90 days prior to the first screening visit.
8. Subject agrees to use a condom during the study until the final return visit to ensure the safety of the study participants and their sexual partner(s)
9. Subjects will refrain from donating blood or plasma during the study.
10. Subjects will not use cannabis or any recreational drugs for at least 120 days before completing Screening and during the study.
11. In the opinion of the investigator, subject is able to adhere to the study requirements, restrictions, schedule of assessments, and requirements related to sperm sample collection and maintenance of the sexual activity diary.

Exclusion Criteria:

1. Men participating in another clinical study involving an investigational drug within the last 90 days prior to the first dosing or less than 5 elimination half-lives prior to first dosing, whichever is longer.
2. Clinically significant abnormal physical and/or laboratory findings at Screening
3. Abnormal serum chemistry values at screening or admission, that indicate liver or kidney dysfunction or that may be considered clinically significant, such as bilirubin of >20 micro mol/L and ALT, AST, GGT and ALP above the upper limit of normal.
4. Evidence of renal impairment at screening, as indicated by an estimated eGFR of <80 mL/min/1.73 m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI; 2009) equation.
5. Use of androgens within 90 days before first screening visit.
6. Ongoing use of body building nutritional supplements.
7. Systolic blood pressure (BP) >140 mmHg (<45 years) or >160 mmHg (≥45 years) and diastolic BP >90 mmHg at screening or predose.
8. Clinically significant abnormal electrocardiogram (ECG) or a duration of corrected QT interval in ECG (QTc) interval of >450 msec at screening or predose.
9. Known history of androgen deficiency due to hypothalamic-pituitary or testicular disease or multiple endocrine deficiencies.
10. Known history of significant cardiovascular, renal, hepatic (cholecystectomy is not permitted), or prostatic disease or significant psychiatric illness. Gilbert's syndrome is allowed (subject will be excluded if total bilirubin is ≥1.5 x ULN if known Gilbert's syndrome). If subject has elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to identify possible undiagnosed Gilbert's syndrome (i.e., direct bilirubin <35% of the total bilirubin).
11. Current or clinically relevant history of any psychiatric disorder or clinical assessment of significant suicidal risk or risk of self-injury as per the Investigator's judgement. This will be re-assessed at admission to Period 2 and Period 3 if applicable.
12. Serious adverse reaction or serious hypersensitivity to any drug or formulation excipients.
13. Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active.
14. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) 1 and 2 antibody results at screening visit.
15. Known or suspected alcoholism or drug abuse within the last 2 years that may affect metabolism/transformation of steroid hormones or study treatment compliance.
16. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator or delegate at screening.
17. Regular alcohol consumption in males >14 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type).
18. Current smokers and those who have smoked within the last 6 months. A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or admission.
19. Confirmed positive drugs of abuse test result.
20. Subjects who are taking, or have taken, any prescribed or over-the-counter drug or vitamins/herbal remedies/supplements (other than up to 4 g of paracetamol per day in the 14 days before IMP administration). COVID-19 vaccines are accepted concomitant medications. Exceptions may apply, as determined by the investigator, if each of the following criteria are met: medication with a short half-life if the washout is such that no PD activity is expected by the time of dosing with IMP; and if the use of medication does not jeopardize the safety of the trial subject; and if the use of medication is not considered to interfere with the objectives of the study.
21. Male subjects with pregnant or lactating partners.
22. Subjects who are taking, or have taken, any prescribed or over-the-counter drug or vitamins/herbal remedies/supplements (other than up to 4 g of paracetamol per day in the 14 days before IMP administration). COVID-19 vaccines are accepted concomitant medications. Exceptions may apply, as determined by the investigator, if each of the following criteria are met: medication with a short half-life if the washout is such that no PD activity is expected by the time of dosing with IMP; and if the use of medication does not jeopardize the safety of the trial subject; and if the use of medication is not considered to interfere with the objectives of the study.
23. Any site staff member with delegated study responsibilities or a family member of a site staff member with delegated study responsibilities.

24. Any other medical condition that, in the opinion of the investigator, could alter the subject's well-being, the study conduct, or the interpretability of the results.

    -

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: YCT-529; Oral single ascending dose(s)	Drug: YCT-529; Single oral dose (planned doses of 10, 30, 90 and 200 mg; dose levels will not exceed 250 mg
Placebo Comparator: Placebo; Placebo for YCT-529 Capsule	Drug: YCT-529 Placebo; YCT-529 Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The incidence and nature of any adverse events, dose-limiting adverse events and serious adverse adverse events.	Assessment of the number and type of adverse events, dose-limiting adverse events and serious adverse events following dosing.	Baseline to 43 days for subjects participating in Cohorts 1 and 2 participating in the 2 periods; Baseline to 10 weeks for Cohorts 1 and 2 that also complete the fed portion of the study; and Baseline to 16 weeks if waiting for other cohorts to finish
Vital signs assessment (heart rate)	Changes from pre-dose values (beats per minute)	Baseline to Day 15
Vital signs assessment (blood pressure)	Changes from pre-dose values (mm hg)	Baseline to Day 15
Vital signs assessment (oral temperature)	Changes from pre-dose values (temperature in celsius degrees)	Baseline to Day 15
12-lead ECG assessment (heart rate)	Changes from pre-dose values (beats per minute)	Baseline to Day 15
12-lead ECG assessment (QT interval)	Changes from pre-dose values for QT internal length (msec)	Baseline to Day 15
12-lead ECG assessment (QTcF Interval)	Changes from pre-dose values for QTcF interval length (msec)	Baseline to Day 15
12-lead ECG assessment (PR Interval)	Changes from pre-dose values for PR interval length (msec)	Baseline to Day 15
12-lead ECG assessment (QRS Duration)	Changes from pre-dose values for QRS duration (msec)	Baseline to Day 15
Clinical laboratory assessments (hematology blood sample tests)	Changes from pre-dose values (Tests: Hemoglobin, Hematocrit, packed cell volume, Red blood cell, erythrocyte count, mean corpuscular volume, mean corpuscular hemoglobin, Mean corpuscular hemoglobin concentration, Platelet count, White blood cell, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils	Baseline to Day 15
Clinical laboratory assessments (coagulation blood sample tests)	Changes from pre-dose values (Tests: Prothrombin time, Activated partial thromboplastin time (APTT), Fibrinogen)	Baseline to Day 15
Clinical laboratory assessments (clinical chemistry blood sample tests)	Changes from pre-dose values (Tests: Sodium, Potassium, Chloride, Bicarbonate, Urea, Creatinine, Bilirubin (total), Bilirubin (direct; only if total is elevated), Alkaline phosphatase, Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Lactate dehydrogenase (LDH), Creatine kinase (CK), Gamma glutamyl transferase (GGT), Protein (Total), Albumin, Calcium, Glucose (fasting), Glucose,Triglycerides (fasting) Cholesterol (total; fasting)	Baseline to Day 15
Clinical laboratory assessments (urine sample tests)	Changes from pre-dose values (Bilirubin, Urobilinogen, Ketones, Glucose, Protein, Blood, Nitrites, pH, Specific gravity, Leukocytes)	Baseline to Day 15

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Plasma PK Parameter of YCT-529 (Area under the curve to Infinity [AUCinf])	Plasma PK Parameter as measured by area under the curve from time 0 extrapolated to infinity [AUCinf],	Pre-dose to 336 hours after dosing
Plasma PK Parameter of YCT-529 (Area under the curve to the last measured concentration [AUC0-t])	Plasma PK Parameter as measured by area under the curve from time 0 to the last measured concentration [AUC0-t]	Pre-dose to 336 hours after dosing
Plasma PK Parameter of YCT-529 (Area under the curve to 24 hours [AUC0--24])	Plasma PK Parameter as measured by area under the curve from time 0 to 24 hours [AUC0--24]	Pre-dose to 336 hours after dosing
Plasma PK Parameter of YCT-529 (Time to maximum concentration [Tmax])	Plasma PK Parameter as measured by time to maximum concentration [Tmax]	Pre-dose to 336 hours after dosing
Plasma PK Parameter of YCT-529 (Terminal elimination half life [T1/2])	Plasma PK Parameter as measured by terminal elimination half life [T1/2]	Pre-dose to 336 hours after dosing
Plasma PK Parameter of YCT-529 (Lag time [Tlag])	Plasma PK Parameter as measured by lag time [Tlag]	Pre-dose to 336 hours after dosing
Plasma PK Parameter of YCT-529 (Volume of distribution [Vz/F])	Plasma PK Parameter as measured by apparent volume of distribution [Vz/F]	Pre-dose to 336 hours after dosing
Plasma PK Parameter of YCT-529 (maximum concentration [Cmax])	Plasma PK Parameter as measured by maximum concentration [Cmax]) of YCT-529, including the effect of food on the PK	Pre-dose to 336 hours after dosing
Pharmacodynamic parameter of YCT-529, including follicle-stimulating hormone	Changes from pre-dose values of follicle-stimulating hormone	Pre-dose to 336 hours after dosing
Pharmacodynamic parameter of YCT-529, including luteinizing hormone	Changes from pre-dose values of luteinizing hormone	Pre-dose to 336 hours after dosing
Pharmacodynamic parameter of YCT-529, including testosterone	Changes from pre-dose values of testosterone	Pre-dose to 336 hours after dosing
Pharmacodynamic parameter of YCT-529, including sex hormone binding globulin	Changes from pre-dose values of including sex hormone binding globulin	Pre-dose to 336 hours after dosing
Plasma PK Parameter of YCT-529 (oral clearance [CL/F])	Plasma PK Parameter as measured by oral clearance [CL/F] of YCT-529, including the effect of food on the PK	Pre-dose to 336 hours after dosing

Collaborators and Investigators

• Sponsor: YourChoice Therapeutics, Inc.
• Investigators: Principal Investigator: Sharan Sidhu, MBChB, Quotient Sciences

Study record dates

Study Major Dates

• Study Start (Actual): December 20, 2023
• Primary Completion (Actual): June 18, 2024
• Study Completion (Actual): June 18, 2024

Study Registration Dates

• First Submitted: May 3, 2023
• First Submitted That Met QC Criteria: October 16, 2023
• First Posted (Actual): October 23, 2023

Study Record Updates

• Last Update Posted (Actual): October 2, 2024
• Last Update Submitted That Met QC Criteria: September 30, 2024
• Last Verified: September 1, 2024

More Information

Terms related to this study

• Keywords: male; sperm motility; male contraception; orally administered; healthy males; vasectomy; non-hormonal; sperm count reduction; impaired spermatogenesis; impaired motility; vasectomized men
• Other Study ID Numbers: YCT-529-01; 1007466 (Other Identifier: IRAS)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No